These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients. Matsunaga T, Sakamaki S, Ishigaki S, Kohda K, Takeda M, Katoh J, Kuroda H, Hirayama Y, Kusakabe T, Akiyama T, Kuga T, Niitsu Y, Masaoka T, Sagawa T, Matsumoto Y. Int J Hematol; 1999 Feb; 69(2):105-11. PubMed ID: 10071460 [Abstract] [Full Text] [Related]
8. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Pajand O, Ziyaeyan M, Mousavi S, Fatolahzadeh B, Hojabri Z, Bahador A, Abdossamadi Z. Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243 [Abstract] [Full Text] [Related]
9. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. Solano C, Muñoz I, Gutiérrez A, Farga A, Prósper F, García-Conde J, Navarro D, Gimeno C. J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510 [Abstract] [Full Text] [Related]
10. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients. Piiparinen H, Helanterä I, Lappalainen M, Suni J, Koskinen P, Grönhagen-Riska C, Lautenschlager I. J Med Virol; 2005 Jul; 76(3):367-72. PubMed ID: 15902704 [Abstract] [Full Text] [Related]
11. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value. Martín-Dávila P, Fortún J, Gutiérrez C, Martí-Belda P, Candelas A, Honrubia A, Barcena R, Martínez A, Puente A, de Vicente E, Moreno S. J Clin Virol; 2005 Jun; 33(2):138-44. PubMed ID: 15911429 [Abstract] [Full Text] [Related]
12. [Evaluation of cytomegalovirus quantification in blood by the R-gene real-time PCR test]. Marque-Juillet S, Touzard A, Monnier S, Fernand-Laurent C, Therby A, Rigaudeau S, Harzic M. Pathol Biol (Paris); 2010 Apr; 58(2):162-5. PubMed ID: 19854587 [Abstract] [Full Text] [Related]
13. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M. Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310 [Abstract] [Full Text] [Related]
15. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S, Torsellini M, Gerna G. J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637 [Abstract] [Full Text] [Related]
20. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J. Rev Invest Clin; 2002 Jul; 54(3):198-203. PubMed ID: 12183888 [Abstract] [Full Text] [Related] Page: [Next] [New Search]